Emkay Reports [ntpc maruti suzuki wipro hindustan unilever colgate ipca ballarpur bank of baroda[

0 views
Skip to first unread message

Deepak Vaishnav

unread,
Nov 5, 2011, 3:29:14 AM11/5/11
to


 

NTPC

In line, maintain estimates and Buy rating

 

BUY

 

CMP: Rs 179                                       Target Price: Rs 204


n     2Q12 PAT of Rs24.2bn is above est. mainly due to previous yr sales of Rs7.6bn. Adjusting for one offs (previous yr sales is not considered to be one-off), APAT stood at Rs25.4bn, in line

n     Has commissioned 660MW and commercialized 1,160MW in YTDFY12 against target commissioning of 4,320MW. Mgmt maintained its target in the concall. We reiterate FY12 is sunset yr of 80IA – expect positive surprises in COD

n     Highlights - (1) PAF of coal plants low at 83.4% but no under-recoveries as cumulative PAF for 1H12 above 85% level and (2) mgmt guided for 90%+ PAF in FY12. Maintain estimates   

n     Positive news to continue 1) higher COD in FY12-sunset yr of 80IA, (2) FY12/13 grossing & (3) in medium-term, acquiring distressed plants. Maintain Buy; Risk - rising interest rates

 

Regards,

Amit Golchha

Research Analyst | Emkay Global Financial Services Ltd. | www.emkayglobal.com | Email : amit.g...@emkayglobal.com 

Board No. : +91-22-66121212 | Extn. : 408 | DID : 66242408 | Mob : +919833357365 |

 

 



 

Maruti Suzuki India Ltd.

Downside risk to earnings persists, Downgrade to HOLD

 

HOLD

 

CMP: Rs1,128                                        Target Price: Rs1,140


n     Results below est. EBIDTA at Rs 5.2bn (est - Rs 5.8bn) and APAT at Rs 2.6bn (est. - Rs 3.4bn). Consider MTM (Rs 1bn)  on royalty as normal exp. as payment due in Nov 2011

n     Demand is skewed towards diesel vehicles. Sales of petrol vehicles registered decline in 1HFY12. Slower ramp up at Manesar plant to limit optimal utilization in the near term

n     Lower FY12/FY13 vols. by 7.9%/2.4% to 1.19/1.5 mn units, EPS by 20%/10% to Rs 63.9/77.6. Factoring in Re/JPY at 1.7/1.64  vs 1.75/1.7 for FY12/13

n     Downgrade to HOLD, see downside risks from lower volumes. Near term upsides arise from depreciating Yen (4% in one day) as MSIL will start hedging its 2HFY12 exposure

 

Regards,

Chirag Shah

Research Analyst | Emkay Global Financial Services Ltd. | www.emkayglobal.com | Email : chira...@emkayglobal.com 

Board No. : +91-22-66121212 | Extn. : 252 | DID : 66121252 | Mob : +919820580701 |

 

 





Wipro Ltd

Some cheer on revenue growth, retain REDUCE

 

REDUCE

 

CMP: Rs368                                        Target Price: Rs360


n     Sep’11 qtr revenue performance was a tad better than expectations and is nearly the 1st beat in 6 qtrs albeit aided by strong performance in the recently acquired SAIC entity

n     IT svcs mgns declined by ~220 bps QoQ( V/s exp of -190 bps) despite strong revenues, weak currency impacted by full impact of wage increments and SAIC consolidation

n     Dec’11 quarter revenue guidance of ~2-4% QoQ is decent however fares unfavorably to peer Infosys (+3.2-5.4% QoQ)

n     Retain REDUCE with a revised TP of Rs 360 (V/s Rs 320 earlier) as we raise our FY12/13E EPS by 2/8.6% driven largely by lower currency resets

 

Regards,

Manik Taneja

Research Analyst | Emkay Global Financial Services Ltd. | www.emkayglobal.com | Email : manik....@emkayglobal.com 

Board No. : +91-22-66121212 | Extn. : 253 | DID : 66121253 | Mob : +919833934924 |

 

 


 

Hindustan Unilever

All levers played out, Downgrade to HOLD

 

HOLD

 

CMP: Rs375                                        Target Price: Rs347


n     Results beat our expectations – Sales growth of 17.8% to Rs 56bn driven by 9.8% volume growth and APAT growth of 21.7% to Rs 6.9bn

n     Soaps and detergents outshine – revenue growth of 21.8% with PBIT margin expansion of 60bps yoy and 320bps qoq –this catalyst played out earlier than expected

n     We believe all the upgrade catalysts have played out and do not see further catalysts in the near term. At CMP, we feel there is limited upside left, if any

n     While we raise our FY12E/13E EPS by 5.9% to Rs 11.8 and by 5.6% to Rs 13.3, respectively, we downgrade the stock to HOLD with a revised TP of Rs 347/share

 

Regards,

Pritesh Chheda

Research Analyst | Emkay Global Financial Services Ltd. | www.emkayglobal.com | Email: pritesh...@emkayglobal.com 

Board No. : +91- 22- 6612 1212 | Extn. : 273 | DID : +91-22- 6612 1273 | Mob : +91 98208 07241

 

 

Sweta Jain

Research Analyst | Emkay Global Financial Services Ltd. | www.emkayglobal.com | Email : sweta...@emkayglobal.com 

Board No. : +91-22-6612 1212 | Extn. : 479 | DID : 6624 2479 | Mob : +9198923 17596 |

 



 

Colgate-Palmolive

Rich valuations… maintain Reduce

 

REDUCE

 

CMP: Rs1,003                                       Target Price: Rs826


n     Sales growth at 19% to Rs 6.6bn, higher than our expectations, is driven by 13% volume growth. APAT (ex-VRS of Rs82mn) at Rs 1.0 bn is marginally below our estimates

n     Volume market shares in key categories of toothpastes and toothbrush witness a decline – 70 bps to 53% and 420 bps and 36.3%, respectively

n     While higher realizations offset input cost pressure, higher A&P spends resulted in 196bps decline in operating margins to 18.4%.

n     Reduce FY12E/FY13E EPS by 4% and 9% to Rs 31.4 and Rs 34.3, respectively. Maintain our Reduce rating on the stock with a target price of Rs 826/share





Ipca Laboratories Ltd

Rocking Performance – Maintain Buy

 

BUY

 

CMP: Rs254                                        Target Price: Rs392


n     IPCA’s Q2FY12 results were above expectations with a) Revenues at Rs6.2bn (up 20% YoY), b) EBITDA at Rs1.5bn (up 34% YoY) and c) APAT at Rs1bn (up 61% YoY)

n     Loss of anti-malarial sales in domestic market was more than compensated by institutional anti-malarial sales in African market

n     Management has guided for 20% growth in top-line in H2FY12 and 1% improvement in overall EBITDA margins in FY12

n     Maintain Buy with a target of Rs392 (14xFY13 EPS)

 

Regards,

Deepak Malik

Senior Research Analyst | Emkay Global Financial Services Ltd. | www.emkayglobal.com | Email : deepak...@emkayglobal.com  

Board No. : +91-22-66121212 | Extn. : 257 | DID : 66121257 | Mob : +91 9769811227 |

 




 

Ballarpur Industries

Margins disappoint, reduce estimates

 

ACCUMULATE

 

CMP: Rs30                                        Target Price: Rs35


n     Q1FY12 results disappointed due to margin pressures. Revenues of Rs 11.1bn, +9% yoy were in line however APAT of Rs 254mn, -38% yoy disappointed due to lower margins

n     Paper realizations increased by 11% yoy/ 3% qoq to Rs 45,000/mt however inventory builtup of 9,000mt impacted sales volumes at 195,800 mt, flat yoy / -5.7% qoq

n     Pulp realizations declined from their peak of Rs 67,700 / mt in Q4FY11 to Rs 56,000/mt in line with estimates. Pulp reported margins of 29.5%

n     We have reduced our FY12 est by 24% to Rs 3.1 due to current margin pressure while expect margins to improve from Q3FY12 on commissioning of pulp plant

 

Regards,

Rohan Gupta

Research Analyst | Emkay Global Financial Services Ltd. | www.emkayglobal.com | Email : rohan...@emkayglobal.com 

Board No. : +91-22-66121212 | Extn. : 248 | DID : 66121248 | Mob : +919619321479 |

 

 



 

Bank of Baroda

Stable quarter

 

ACCUMULATE

 

CMP: Rs772                                        Target Price: Rs950


n     BOB’s Q2FY12 NII at Rs25.7bn and PAT at Rs11.6bn above our/consensus estimates. PAT further aided by higher non-interest income

n     Balance sheet expanded 4.7% sequentially; growth in deposits / loans came in at 5.2% / 2.9% qoq respectively. Domestic NIM up 28bps qoq to 3.67%

n     Asset quality remains stable sequentially. Slippages came in at Rs4.9bn (0.9% annualized). However, reco/upgrade rates equally lower at 24% of opening GNPAs

n     Valuations at 1.3x/1.1x FY12E/FY13E ABV. Upgrade to ACCUMULATE on recent correction with price target of Rs950

 

Regards,

Kashyap Jhaveri

Research Analyst | Emkay Global Financial Services Ltd. | www.emkayglobal.com | Email : kashyap...@emkayglobal.com 

Board No. : +91-22-6612 1212 | Extn. : 249 | DID : +91-22-6612 1249 | Mob : +91-98202 41712 | Fax : +91-22-6624 2410 |

 

 



image001.gif
image001.gif
image002.gif
image001.gif
image001.gif
image002.gif
image001.gif
NTPC Q2FY12 Result Update.pdf
Maruti Suzuki Q2FY12 Result Update.pdf
Wipro Q2FY12 Result Update.pdf
Hindustran Unilever Q2FY12 Result Update.pdf
Colgate Palmolive Q2FY12 Result Update.pdf
IPCA Lab Q2FY12 Result Update.pdf
Ballarpur Industries Q1FY12 Result Update.pdf
Bank of Baroda Q2FY12 Result Update.pdf
Reply all
Reply to author
Forward
0 new messages